CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
OPERATING EXPENSES
Research and development	$ 6,394,534	$ 6,231,908	$ 20,063,752	$ 17,985,937
Financing costs (Note 7)	3,145	16,667	10,996	18,147
General and administration	2,895,542	3,117,900	9,775,082	9,942,149
Total operating expenses	(9,293,221)	(9,366,475)	(29,849,830)	(27,946,233)
Foreign exchange	910	(34,084)	30,338	(19,239)
Interest and other income	417,872	80,394	974,207	155,293
Derivative liability gain (loss) (Note 8)	1,929	568,954	20,352	(470,132)
Net loss for the period before taxes	(8,872,510)	(8,751,211)	(28,824,933)	(28,280,311)
Income tax recovery (expense)	45,767	(800)	45,667	34,349
Net loss for the period	(8,826,743)	(8,752,011)	(28,779,266)	(28,245,962)
OTHER COMPREHENSIVE LOSS
Unrealized loss on short-term investments	(2,951)		(51,682)
Loss and comprehensive loss for the period	$ 8,829,694	$ 8,752,011	$ 28,830,948	$ 28,245,962
Earnings Per Share [Abstract]
Basic loss per common share	$ (0.20)	$ (0.21)	$ (0.65)	$ (0.76)
Diluted loss per common share	$ (0.20)	$ (0.21)	$ (0.65)	$ (0.76)
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Weighted average number of common shares outstanding - Basic	44,059,700	41,018,024	44,026,502	36,937,014
Weighted average number of common shares outstanding -Diluted	44,059,700	41,018,024	44,026,502	36,937,014